Filing Details

Accession Number:
0000899243-19-009178
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-28 17:29:52
Reporting Period:
2019-03-26
Accepted Time:
2019-03-28 17:29:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348911 Kalvista Pharmaceuticals Inc. KALV Pharmaceutical Preparations (2834) 200915291
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1367381 Sv Life Sciences Fund Iv, L.p. One Boston Place
201 Washington Street, Suite 3900
Boston MA 02108
No No Yes No
1392309 Sv Life Sciences Fund Iv Strategic Partners, L. P. One Boston Place
201 Washington Street, Suite 3900
Boston MA 02108
No No Yes No
1422339 Svlsf Iv, Llc One Boston Place
201 Washington Street, Suite 3900
Boston MA 02108
No No Yes No
1422340 Sv Life Sciences Fund Iv (Gp), L.p. One Boston Place
201 Washington Street, Suite 3900
Boston MA 02108
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-26 29,262 $29.70 1,907,090 No 4 S Direct
Common Stock Disposition 2019-03-26 831 $29.70 54,142 No 4 S Direct
Common Stock Disposition 2019-03-27 56,318 $29.06 1,850,772 No 4 S Direct
Common Stock Disposition 2019-03-27 1,599 $29.06 52,543 No 4 S Direct
Common Stock Disposition 2019-03-28 35,653 $27.80 1,815,119 No 4 S Direct
Common Stock Disposition 2019-03-28 1,012 $27.80 51,531 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.68 to $30.01, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. These shares are held directly by SVLS IV LP.
  3. SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein.
  4. These shares are held directly by Strategic Partners.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $30.425, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $29.10, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.